The company attributes the better numbers to all-around improvement in sales of its products, especially that from its so-called speciality pharma principals segment, which has rebounded from supply chain woes in 1HFY2023.
Hyphens Pharma International has reported 97.6% higher y-o-y earnings of $2.7 million for 1QFY2024, nearly double that of the year-earlier period.
Revenue in the same three months ended March increased by 44.4% to $48 million.
